Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. ALAR
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SKA-B
10. PBA

Go back to Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Incyte (INCY): Tumor Removal Drives Estimate Cut - UBS

February 12, 2016 8:57 AM EST

UBS analyst, Matthew Roden, looked through a good quarter for Incyte (NASDAQ: INCY) to the importance of pipeline growth. He adjusted his model to remove the contribution of Jakafi in solid tumors which led him to cut his PT to $88 from $110. No change to the Buy rating though as the new PT implies 35% upside.

Although 4Q operations beat cleanly on the top/bottom lines, 2016 opex guidance and in particular the failure of Jakafi in solid tumors caused a PT cut to $88 (from $110) as solid tumors (and '110) are removed from the model. Risk-adjusted... More